Introduction

Knee osteoarthritis is a widespread and often painful condition that affects many people across the UK. With more patients seeking new, less invasive treatments, Arthrosamid has caught the eye as a promising injectable therapy offering longer-lasting relief. Although it has secured regulatory approval and can be accessed privately, Arthrosamid is not yet available on the NHS, leaving many patients puzzled and eager to understand why.

How the NHS Approves New Treatments

Getting a new treatment onto the NHS isn’t straightforward. The National Institute for Health and Care Excellence (NICE) plays a crucial role by carefully reviewing the safety, effectiveness, and cost value of new drugs and devices. Even once a treatment like Arthrosamid has its market licence or CE-mark, it must pass further tests. These include submitting detailed clinical trial results and cost-effectiveness data. NHS funding is only granted when there is clear proof that a treatment benefits patients and represents good value for public funds.

Where Arthrosamid Stands in UK Regulation

It’s important to remember that a treatment’s approval to be sold on the market isn’t the same as getting NHS backing. Arthrosamid has regulatory approval for private use but does not yet have the NHS green light. One recent review highlighted “statistically significant results at 2 years,” pointing to lasting benefits (Cole et al., 2022). However, NHS decision-makers require more extensive, long-term evidence before they can recommend it routinely. Ongoing studies are expected to fill these gaps in the near future.

Accessing Arthrosamid: Private vs NHS Routes

Right now, the only way for many patients to receive Arthrosamid treatment is privately, where the rules and budgets differ. Private care often means quicker appointments but involves paying out of pocket. On the NHS, treatments must demonstrate strong patient benefits under strict budget constraints – which means newer therapies can face delays in approval. Research shows “iPAAG offers comparable short-term efficacy and modest advantage at 6 months” compared to common injections (Aykaç et al., 2025). While patients frequently ask when it will become available on the NHS, it depends on the progress of regulatory reviews, so staying updated through NHS sources and healthcare professionals is advised.

The Importance of Cost-Effectiveness and Public Health Priorities

For NHS adoption, demonstrating cost-effectiveness is essential. This means Arthrosamid must show clear health benefits that justify its cost, especially against existing treatments already funded by the NHS. Safety is equally important: evidence confirms that “injection of PAAG hydrogel… has been shown to be safe with no long-lasting adverse events reported” (Cole et al., 2022). Laboratory studies also confirm that “2.5 iPAAG demonstrates no apparent neurotoxicity or cytotoxicity in human nerve cells” (Walmod et al., 2025). Despite these positive signs, some research points out that “long-term superiority is limited,” meaning more studies are needed to fully establish where Arthrosamid fits best within osteoarthritis care (Aykaç et al., 2025). Given NHS budget pressures and competing health priorities, decisions weigh heavily on such detailed evidence.

What Needs to Happen Before Arthrosamid Joins NHS Treatments

For Arthrosamid to be routinely available on the NHS, it still needs to pass through further robust clinical trials and cost-effectiveness assessments. Experts expect these next steps and official health technology reviews may take a few years. In the meantime, patients have access to a range of well-established NHS treatments for knee osteoarthritis and should discuss their options with healthcare providers. Keeping an eye on NHS announcements will also help patients stay informed as research and regulatory decisions evolve.

Conclusion

To sum up, Arthrosamid’s absence from NHS treatment lists is due to a careful and sometimes lengthy process that ensures every treatment is safe, effective, and good value for public health spending. While it shows real promise, more high-quality evidence and formal appraisal are required before it can be widely offered through the NHS. Patients and clinicians alike should stay engaged in conversations about current treatment options and watch for updates on ongoing research and policy decisions that could bring Arthrosamid to the NHS in the future.

References

• Cole, A., Maulana, R., Whitehead, J., & Lee, P. (2022). A Systematic Review of the Novel Compound Arthrosamid Polyacrylamide (PAAG) Hydrogel for Treatment of Knee Osteoarthritis. Medical Research Archives, 10(8). https://doi.org/10.18103/mra.v10i8.2950
• Aykaç, B., Dinç, M., Nar, Ö. O., Karasu, R., & Bayrak, H. Ç. (2025). Comparative efficacy of polyacrylamide hydrogel versus hyaluronic acid and corticosteroids in knee osteoarthritis: A retrospective cohort study. Medicine, 104(9). https://doi.org/10.1097/MD.0000000000044655
• Walmod, P. S., Kusk, P., Jøhnk, N., Ankorina-Stark, I., & Essex, A. (2025). An injectable 2.5% cross-linked polyacrylamide hydrogel (2.5 iPAAG) demonstrates no neurotoxicity in human induced pluripotent stem cells-derived iCell® GlutaNeurons. Frontiers in Toxicology. https://doi.org/10.3389/ftox.2025.1585430